ISPOR - Reviewing Adverse Drug Event Reporting Between Randomized Clinical Trial Data and Real World Post Market Data for Sorafenib and Sunitinib

Full Text

Reviewing Adverse Drug Event Reporting Between Randomized Clinical Trial Data and Real World Post Market Data for Sorafenib and Sunitinib

Abstract

Authors

AE Grothen DR Rivera

Back to Volume 21, Supplemental S1

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now